Analyst Price Target is $53.25
▲ +34.47% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Harmony Biosciences in the last 3 months. The average price target is $53.25, with a high forecast of $58.00 and a low forecast of $43.00. The average price target represents a 34.47% upside from the last price of $39.60.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Harmony Biosciences.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.